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Abstract
Background: Neuropathic pain affects 7–10% of people, but responds poorly to pharmacotherapy, indicating a
need for better treatments. Mechanistic research on neuropathic pain frequently uses human surrogate models of
the secondary hyperalgesia that is a common feature of neuropathic pain. Experimentally induced secondary
hyperalgesia has been manipulated with pharmacological and non-pharmacological methods to clarify the relative
contributions of different mechanisms to secondary hyperalgesia. However, this literature has not been systematically
synthesised. The aim of this systematic review is to identify, describe, and compare methods that have been used to
manipulate experimentally induced secondary hyperalgesia in healthy humans.
Methods: A systematic search strategy will be supplemented by reference list checks and direct contact with identified
laboratories to maximise the identification of data reporting the experimental manipulation of experimentally induced
secondary hyperalgesia in healthy humans. Duplicated screening, risk of bias assessment, and data extraction procedures
will be used. Authors will be asked to provide data as necessary. Data will be pooled and meta-analyses conducted
where possible, with subgrouping according to manipulation method. Manipulation methods will be ranked for potency
and risk.
Discussion: The results of this review will provide a useful reference for researchers interested in using experimental
methods to manipulate secondary hyperalgesia in humans and will help to clarify the relative contributions of different
mechanisms to secondary hyperalgesia.
Systematic review registration: This protocol will be registered on PROSPERO before the review begins. Review records
will be updated on PROSPERO once the review is complete. This review is intended for publication in a peer-reviewed
journal. Analyses and scripts will be made publicly available.
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Introduction
Rationale
Neuropathic pain (NP) currently affects 6.9–10% of the
general population [1] and has severe consequences for
the individual and for society. In a multicentre cohort
survey, 2 in 3 people with NP had suboptimal sleep, 1 in
3 had a current mood disorder, over 90% reported
feeling “sadness most of the time” and “tired most of the
time”, and 18% had a current risk of suicide [2]. These
findings are consistent with other reports that NP is
associated with decreased life participation, low health-
related quality of life, poor mental health, poor physical
function, and higher use of health care services [3, 4].
The problem is only perpetuated by the fact that NP
treatments perform poorly: the numbers needed to treat
for even the first-line drugs range from 3.6 to 7.7 [5].
Given the severe consequences of NP and the obvious
need for better treatments, understanding the mecha-
nisms of NP is an important priority for health care
research.
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Secondary hyperalgesia—increased pain to a stimulus
that is normally painful, in the area outside that of tissue
damage or stimulation—is a common feature of NP [6].
Although a single model cannot account for all the pos-
sible features of clinical NP, experimentally induced
secondary hyperalgesia has been widely used as a
laboratory-based human surrogate model in studies that
aim to elucidate the mechanisms that underlie neuro-
pathic pain [7–11]. Methods that have been used to
induce this secondary hyperalgesia in the experimental
context include the application of capsaicin (intradermal
or topical), topical mustard oil, topical menthol, repeti-
tive heating, and high-frequency electrical stimulation
[6, 9]. While secondary hyperalgesia is typically consid-
ered the primary outcome of studies that use these
inductions, secondary outcomes may include primary
hyperalgesia, secondary allodynia, and the surface area of
secondary hyperalgesia. These outcomes can be com-
pared to identify the relative contributions of different
mechanisms. For example, while capsaicin-induced primary
hyperalgesia could be attributed to changes in both periph-
eral and central nervous system processing, the broader dis-
tribution of secondary hyperalgesia suggests that it is
mediated by changes in central processing [12].
Individual responses to an induction of secondary
hyperalgesia can be useful for identifying certain profiles
of sensitivity and factors that may be linked to those
profiles. For example, in a small pilot study, women with
a history of trauma showed a greater surface area of sec-
ondary hyperalgesia than women who did not have a
history of trauma, after both groups underwent the same
induction procedure [13]. This profiling may also have
direct clinical application: the magnitude of induced sec-
ondary hyperalgesia could be useful for grouping pa-
tients by phenotype in order to better predict their
responses to treatment [14].
As a surrogate model for NP, experimentally induced
secondary hyperalgesia can be manipulated using
pharmacological, psychological, or physical techniques,
with a view to identifying potential treatments. The
NMDA antagonist, Ketamine, has been found to reduce
secondary hyperalgesia induced by capsaicin [15]. Nega-
tive expectations have been linked to greater secondary
hyperalgesia induced by electrical stimulation [16], and
an emotional disclosure intervention reduced the surface
area of secondary hyperalgesia induced by capsaicin in
women with a prior history of trauma [17]. A potential
treatment that shows promise in animal studies can be
tested in humans using the secondary hyperalgesia
model as a step in the process towards refining and test-
ing the treatment for clinical use.
Manipulating experimentally induced secondary
hyperalgesia with interventions that have clinical poten-
tial is an important line of inquiry towards developing
viable treatments for the relief of NP. However, although
numerous studies have manipulated secondary hyper-
algesia, there has been no attempt to systematically
synthesise and appraise the literature on this topic.
Aims and objectives
Aim
With this study, we aim to systematically identify,
collate, and describe all the published studies that have
applied manipulations intended to influence experimen-
tally induced secondary hyperalgesia in healthy human
participants. In doing so, we hope to provide a resource
that will summarise the literature to date, provide pooled
effect size estimates where possible, and identify gaps in
knowledge and opportunities for further inquiry. There-
fore, the primary aim of this systematic review is to
identify, describe, and compare methods that have been
used to manipulate experimentally induced secondary
hyperalgesia in healthy humans.
Objectives
1. To identify methods used to manipulate secondary
hyperalgesia
2. Describe each method in terms of procedure,
essential equipment required, pain reported by
participants during manipulation and harm
reported in studies using each method
3. Determine the effect of each manipulation on
a. The magnitude of static mechanical secondary
hyperalgesia





We will include published and in-press or accepted records
for which title, abstract, and full-text versions are available
in English. Only prospective experimental studies will be in-
cluded, that is, studies that attempted to manipulate second-
ary hyperalgesia for the purpose of studying the effects of
the manipulation, and that did so in the context of an ex-
periment, such that the secondary hyperalgesia was not a
naturally occurring clinical phenomenon. In other words,
participants must have begun the study without the second-
ary hyperalgesia being studied. To be eligible, studies must
have assessed secondary hyperalgesia within 120min after
induction (so as not to miss the anticipated peak of the
effect).
Types of study participants
We will include data from healthy human participants
only. We place no restriction on the age of participants,
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but data from adults will be treated separately from data
from children (< 18 years old).
Types of interventions
We will include data from experimental studies that aimed
to manipulate secondary hyperalgesia (defined as “increased
pain from a stimulus that normally provokes pain” [18] in
an area adjacent to the stimulated area). Studies that ma-
nipulate secondary hyperalgesia as one step in a larger study
will be considered eligible, provided that suitable baseline/
control data are available to allow for estimation of the effect
of the manipulation on secondary hyperalgesia.
Types of outcome measures
Pain will be defined as “an unpleasant sensory and emo-
tional experience associated with actual or potential
tissue damage, or described in terms of such damage”
[18]. Pain must be measured by subjective self-report.
Therefore, studies must have assessed the subjective
(participant-reported) intensity of pain or sensation to
somatosensory stimulation.
Primary outcome
The primary outcome is secondary hyperalgesia. Studies
must have assessed mechanical secondary hyperalgesia (spe-
cifically, participant self-report to punctate mechanical
stimulation) applied to the area surrounding the induction/
manipulation site. Further, in order to qualify as “hyperalge-
sia”, the post-manipulation assessment must be compared
to a within-subject control site (e.g. opposite limb on which
induction but not manipulation was performed) or time
point (e.g. after induction but before manipulation or, in the
case of repeated inductions, to the same induction proced-
ure performed without manipulation) or a between-subject
control (e.g. group that underwent induction without the
manipulation).
Secondary outcomes
 Surface area of secondary hyperalgesia, as measured
using reproducible methods (such as a radial lines
approach [11, 13, 15])
 Time course of secondary hyperalgesia
 Pain (except to test stimulation) reported during and
after manipulation procedure
 Risks of the manipulation, defined as adverse events
(e.g. skin damage, other adverse reaction)
Search methods for identification of studies
Electronic searches
We will search the following electronic databases with a
strategy that spans the time from their inception to the
date of the search:
 Biosis (via Web of Science)






 Web of Science Core (use to search and then use
menu on left to filter for Core option and Biosis)
The search strategy will be:
((“human*” OR “women” or “woman” OR “man” OR
“men” OR “participant*” OR “volunteer* OR individual*”)
OR
“normal skin” OR “healthy skin”)
AND
(“secondary hyperalgesia” OR “punctate hyperalgesia”
OR “pinprick pain” OR “pinprick hyperalgesia” OR
“mechanical hyperalgesia” OR “mechanical pain” OR
“heat hyperalgesia” OR “neurogenic hyperalgesia”))
with all terms searched for in the title, keywords, or
abstract.
+ limit to humans when possible in each database.
Other sources
We will check reference lists of eligible studies to check for
other eligible studies not identified by electronic searching.
We will also contact experts in the field and the corre-
sponding authors of the most recent narrative reviews on
experimental induction and manipulation of secondary
hyperalgesia to ask for their assistance in identifying any
missed studies (including Walter Magerl, Rolf Baron,
Jürgen Sandkühler, Mark Wallace, Peter Drummond). We
will also request any unpublished data from labs that have
published extensively on these techniques, including data
obtained during model development or optimisation.
Data collection and analysis
Data management
The Systematic Review Facility (http://syrf.org.uk/) will
be used to manage the review process.
Study selection
Two of three reviewers (VJM, GJB, and PC) will independ-
ently screen each identified record for eligibility in two se-
quential stages, screening (stage 1) title and abstracts and
(stage 2) full texts. We will contact study authors a max-
imum of three times to obtain additional information that
could influence eligibility. A customised eligibility form (see
table below) will be used to record decisions in stage 2. Any
disagreements about study inclusion will be resolved by dis-
cussion or by adjudication from a fourth, independent re-
viewer (PRK) if necessary. The study selection process will
be reported using a PRISMA flow diagram.
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Inclusion/exclusion criteria and grouping table
Assessment of risk of bias
A risk of bias assessment will be completed on each
study. Two reviewers will independently appraise the
risk of bias for the domains of selection, performance,
detection, attrition, measurement, reporting, and other
sources of bias. The criteria used to rate the risk of
bias will be based on recommendations from the
Cochrane collaboration [19] known quality instru-
ments (e.g. the CONSORT [20] and STROBE [21]
statements as relevant) and on known areas of bias
relevant to the study design used [22], and are speci-
fied in the risk of bias assessment tool and guide (see
Additional file 1). We will pilot the form on 2–3
studies and adapt it prior to formal application to all
included studies. The focus of the risk of bias assess-
ment will be on the risk that the data to be extracted
to answer the questions of this review could be
biased. The appraisals of the two independent re-
viewers will be compared and any disagreements re-
solved through discussion and consensus, or by third
party adjudication if necessary.
Data extraction and management
Two of reviewers will independently extract data from
each included study, using a standardised data extrac-
tion form. We will pilot and refine the data extraction
form using 2–3 studies beforehand. We will contact
study authors a maximum of 3 times to obtain re-
quired data that are unavailable or unclear from the
published texts. If no reply is received within 6 weeks,
we will consider the data unavailable. If the relevant
data are not provided within 6 weeks of the first
reply, we will consider the data unavailable for this
review. Published data that seem implausible will be
verified directly with the corresponding author where
possible. Reviewers will resolve disagreements by dis-
cussion and consensus, or by a third party adjudica-
tion if necessary.
Study design We will extract data on the study design,
including the location/setting, date, sample size, primary
aim, and outcomes measured.
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Participants We will extract data on the participants,
including number, age, sex, pain status and sites of pain,
co-morbid diagnoses, and psychological variables.
Interventions We will extract data on the interven-
tion(s) used to manipulate secondary hyperalgesia, in-
cluding timing, duration, dosage (e.g. intensity or
concentration), method of administration, modality, site,
adverse effects, and ease of application where relevant.
We will extract data on the equipment used (e.g. elec-
trodes, needles, images, scripts). We will extract data on
the control (site and/or time point and/or group). We
will extract data on the manipulation check, where rele-
vant (e.g. for psychological manipulations).
Outcomes We will extract data on the test stimulus mo-
dalities, the scale or measure used to assess pain or
change in perceived intensity, and the timing of assess-
ments, that is, time from induction to first measure-
ments and to each subsequent measurement, in minutes.
We are interested in the following outcomes:
1) Secondary hyperalgesia intensity to calibrated
punctate mechanical stimulation (e.g. Von Frey
filament or calibrated pinprick stimulator)
2) The surface area affected by secondary hyperalgesia
as tested in [1]
3) The duration of secondary hyperalgesia as tested
in [1]
Where studies have included other outcomes associated
with changes in secondary hyperalgesia (e.g. changes in
brain activity shown on imaging), and when the secondary
hyperalgesia data for that study indicate that the manipula-
tion successfully influenced secondary hyperalgesia, we will
discuss the findings as they pertain to the other outcomes.
Results We will extract data on the participants in each
study (including age, sex) the baseline and follow-up rat-
ings for experimental and control sites for each partici-
pant or group, for each outcome. We will extract the
number of participants who reported adverse effects and
the number and natures of adverse effects reported.
Measures of intervention effects
When determining the potency of each manipulation
method, our goal is to estimate the size of the effect of
the manipulation by comparing the post-manipulation
outcomes with the pre-manipulation outcomes and/or a
control site/condition/group. For manipulations that are
thought to have localised effects, a within-subject control
site will be considered acceptable. For manipulations
that are thought to have time-limited effects, a within-
participant control time point will be acceptable. For
manipulations that are thought to have systemic effects,
a between-subject control or a control time-point (with
suitable washout period) will be required. Data will be
requested from authors where necessary.
Pooling of data
Data from different studies will be quantitatively pooled
where possible and sensible, with subgrouping according
to modality of induction/manipulation (e.g. negative
expectation manipulation will be grouped separately to
ketamine manipulation) and outcome (e.g. secondary
hyperalgesia to mechanical punctate stimulation will be
grouped separately to secondary allodynia to brush
stroke), and with consideration given to measures of stat-
istical heterogeneity (e.g. I2 statistic) and sensitivity ana-
lyses that exclude studies with particularly high risk of
bias and studies in which obvious sources of methodo-
logical heterogeneity have been identified. This is not an
individual patient data meta-analysis. We plan to use the
RevMan software [23] or the R software with the package
metafor to pool data and plot pooled data. The most up-
to-date version of the relevant software package will be
used. The outcome measure will be a standardised mean
difference. We will use a random effects model to allow
for anticipated heterogeneity between studies.
Where data exist but are unavailable, we plan to discuss
the information that is available (e.g. number of partici-
pants tested, reasons for data unavailability, methods used)
in narrative form, so as to mitigate against publication bias
and provide a comprehensive summary of the literature
available to answer the review question.
Relative ranking of interventions
If the quantity and quality of data allow, we will compare
the pooled effect sizes (where available) to rank the dif-
ferent manipulations in the order of potency and risk. If
the results reveal different potencies for the different
outcomes of interest, then these ranked lists will be
compiled separately for the different outcomes.
Publication bias
We will use funnel plots to examine for publication bias.
Assessment of the quality of the body of evidence
We will use the GRADE criteria [24] to assess the qual-
ity of the body of evidence for each manipulation, wher-
ever more than one study is available for a certain
manipulation.
Publication and dissemination plan
We will update the review records on PROSPERO once
the review is complete. We aim to publish this review in
a peer-reviewed journal and to make all analyses and
scripts publicly available.
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Reporting
Please see Additional file 2 PRISMA-P checklist for the
elements included in this protocol.
Additional file
Additional file 1: Risk of bias assessment tool. (DOCX 26 kb)




VJM conceived and developed the protocol; piloted the procedure; refined,
finalised, and submitted the protocol, and approved the final version of the
protocol. GJB piloted the procedure, refined the protocol, and approved the
final version of the protocol. PC refined and approved the final version of
the protocol. ASCR approved the final version of the protocol. PRK refined
and approved the final version of the protocol.
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